Építés alatt – nem éles oldal
Belépés
Résztvevőt keresFázis nélkül

Stereotactic Radiotherapy in Oligometastatic Brain Disease: a Randomised Phase III Study Comparing Hypofractionated Stereotactic Radiation Therapy (3*10 Gy) to the Historical Single-dose Radiosurgery (1*20 to 25 Gy) With Medico-economic Evaluation.

A legfontosabb adatok

Ki végzi
Centre Francois Baclesse
Hol
Franciaország15 helyszín, 1 országbanVálassz országot a helyszínekhez
Azonosító
Állapot
Toboroz
Résztvevők
504 fő, tervezett
Kezdés
2023. jan. 12.
Várható befejezés
2031. jan.
A vizsgálat típusa
Beavatkozással járó, 2 csoportAz egyik csoport egy már használt kezelést kap, összehasonlításként.
A vizsgált kezelések
  • Hypofractionated SRT (stereotactic radiotherapy)
  • Historical single-dose SRS (stereotactic radiosurgery)
A regiszteradat frissítve
2026. január 27.

Ki vehet részt

MI-összefoglaló

A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.

The trial is looking for adults with 1 to 5 brain metastases from a solid tumour. It compares radiotherapy given in 3 sessions with a single-session radiosurgery.

Életkor
18 years and older
Nem
All sexes
A betegség stádiuma
Up to 5 brain metastases from a solid tumour proven by tissue test. At least 1 and no more than 5 target lesions measuring between 10 and 25 mm. Total tumour volume at most 30cm3. WHO performance status 0 or 1. People who had a brain metastasis removed by surgery and have 1 to 4 lesions can join. Brain metastases causing symptoms are allowed. A minimum DS-GPA prognosis score is required for some cancer types (for example renal and breast cancer 2,5 or more, melanoma 1.5 or more).
Korábbi kezelés
No earlier stereotactic radiotherapy to the brain and no earlier whole-brain radiotherapy. Ongoing cancer drug treatment must be paused 3-7 days before and after the radiotherapy.
Biomarker vagy leletérték
Normal complete blood count.

A részvétel fő kizáró okai

  • Small cell lung cancer, germ-cell tumours, lymphoma, leukemia or multiple myeloma within the last 5 years
  • Metastases in the brain stem or within 1 cm (0,4 in) of the optic nerves, or bleeding metastases or spread to the brain lining
  • A neurodegenerative disease, or long-term corticosteroid use for reasons other than the cancer
  • Unable to have a brain MRI or contrast agent
  • Known pregnancy or breastfeeding

A regiszter feltételei, szó szerint

Mind a 32 feltétel megnézéseKevesebb

Ki vehet részt

  • Patients aged ≥ 18 years
  • WHO performance status 0 or 1
  • Patient eligible for SRT after a multidisciplinary committee decision; Patient with BMs from radioresistant cancer (renal cell carcinoma, sarcoma, melanoma) is eligible
  • Patient having up to 5 BM of solid tumours with an histologically proven diagnoses; patients who have had a metastasectomy and having 1 to 4 BM lesions is eligible (ANOCEF recommendations); post-operative cavity must be treated by radiosurgery according to local procedures with respect of non-inclusion criteria* (cavity will not be analyzed for efficacy)
  • Presence of at least one and no more than 5 target lesions for SRT, measuring between 10 and 25 mm. In the event of synchronous BM, lesions measuring less than 10mm or more than 25mm (1 to 4 lesions) will be treated at the discretion of the investigator
  • Max cumulative GTV of 30cm3
  • Normal complete blood count (CBC)
  • Absence of bleeding BM or meningeal carcinomatosis
  • Symptomatic BM are allowed
  • DS-GPA score:; Renal cancer: DS-GPA 2,5 or more; Breast cancer: DS-GPA 2,5 or more; Melanoma: DS-GPA 1.5 or more; Gastro-instestinal (GI) cancer: DSGPA 3 or more; Adenocarcinoma lung cancer: DS-GPA 2 or more (DS-GPAmol); Squamous lung cancer : DS-GPA 2,5 or more (DS-GPAmol); For cancers where the DS-GPA score is not applicable, the patient is eligible if eligibility criteria are met
  • Patient with no concomitant systemic treatment; in case of ongoing systemic treatment, wash out period of 3-7 days before and after SRT, depending of drug and at the discretion of investigator
  • Patient sufficiently cooperating to perform the treatment with the use of a thermoformed mask
  • Patient whose neuropsychological abilities allow to follow the requirements of the protocol
  • Female with childbearing potential must use adequate contraception
  • Signed informed consent formOligoBM-01 Trial - ID-RCB number: 2021-A01622-39 - version 3.1 dated from 2023-06-22 Page 9 of 51
  • Patients affiliated to the social security system

Ki nem vehet részt

  • Patients with previous brain stereotactic irradiation
  • Whole brain irradiation history
  • Ongoing anti angiogenic treatment (treatment should be held 3-7 days before irradiation and re-initiated 3-7 days after irradiation for patient to be eligible)
  • Patients with too close brain lesions for whom a treatment plan on one target metastasis delivers a dose > 5 Gy on other concomitant metastasis
  • Patients with current or past history small cell lung cancer, germ-cell tumours, lymphoma, leukemia and multiple myeloma within the last 5 years
  • Patients with an associated neurodegenerative disease
  • Any symptoms not attributable to BM or cancer disease requiring long term corticosteroid use (regardless of dose)
  • Known hypersensitivity to the contrast product or to any their excipients
  • Any geographical conditions, social and associated psychopathology that may compromise the patient's ability to participate in the study
  • Patients with metastases in the brain stem, or within 1 cm of the optic apparatus
  • Contraindication to perform the brain MRI or gadolinium or iodinated contrast
  • Haemorrhagic metastasis
  • Patient deprived of liberty or under guardianship
  • Known pregnancy or breastfeeding
  • Participation in a therapeutic trial for less than 30 days
  • Patient deprived of freedom or under guardianship

Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.

Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

Brain metastases (BM) are a common systemic cancer manifestation which incidence increases. Therapeutic options include whole-brain radiotherapy (WBRT), surgery, and stereotactic radiosurgery (SRS). The concept of "oligometastatic" cerebral disease (oligoBM) has emerged and led to consider alternative approaches. The main challenge is to preserve neurological function and independence the longest as possible.

A teljes eredeti leírásKevesebb

Stereotactic radiotherapy (SRT) has emerged as an alternative treatment modality for selected oligoBM patients. It allows to achieve the balance of tumour destruction and normal tissue preservation by precisely and accurately delivering a very high dose of radiation in one (SRS) or a few (HSRT) fractions to a limited, well-defined volume. However, no standard exists for decision-making between SRS and HSRT and this important question is being discussed in the recent literature.

HSRT appears particularly interesting, assuming the patient convenience of few fractions, the normal tissue sparing achieved through focal irradiation, and the improved normal tissue tolerance of high dose radiation through fractionation.

Common adverse effects of SRT are rare but can occasionally be serious, notably radionecrosis that may induce neurological deficits in patients. Although SRS is often less well-tolerated, it remains the mainstay of treatment.

To investigators knowledge, SRS and HSRT have not been prospectively compared.

A vizsgálat 2 csoportja

  • Hypofractionated SRT (stereotactic radiotherapy)A vizsgált kezelés
  • Historical single-dose SRS (stereotactic radiosurgery)Már használt kezelés, összehasonlításként

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 15.
A regiszteradat frissítve
2026. január 27.